指南与共识关节外科

2018年Chitranjan S. Ranawat医学博士奖:制定并实施新型机构指南策略减少全膝关节置换术和全髋关节置换术后阿片类药物处方

The 2018 Chitranjan S. Ranawat, MD Award: Developing and Implementing a Novel Institutional Guideline Strategy Reduced Postoperative Opioid Prescribing After TKA and THA.
指南 / 共识 · Clin Orthop Relat Res · 2019-01-01

本研究在单一三级医疗中心比较了实施新型阿片类药物处方指南前后初次全膝关节置换术(TKA)和全髋关节置换术(THA)阿片类药物未耐受患者的情况。指南推荐术后最大处方量为400口服吗啡当量(OME)。实施指南后处方中位数从750 OME降至388 OME,而30天续方率无显著差异。机构指南实施是与处方量≤400 OME相关的最强因素(调整比值比36,95%CI 25-52)。

要点

  • 指南推荐TKA和THA术后最大阿片类药物处方量为400 OME,相当于50片5 mg羟考酮或80片50 mg曲马多。
  • 实施指南后阿片类药物处方中位数从750 OME降至388 OME(差值362 OME,p<0.001)。
  • TKA和THA患者30天续方率在指南实施前后无显著差异。

核心结论

  • 本研究提供了概念验证,即减少术后阿片类药物处方的机构指南可在短时间内改善关节置换术患者的后续照护。
  • 当前报告评估了该计划前5个月的经验,因此需要更长期数据以确定纵向指南依从性以及试验性计划建立的截断值是否需要针对各手术进一步细化。

研究设计与样本

  • 单中心三级医疗中心指南实施前后比较研究,证据等级为II级治疗性研究。
  • 指南实施后队列为2017年8月1日至2017年12月31日的阿片类药物未耐受初次TKA和THA患者(n=751)。
  • 指南实施前队列为2016年同一机构的阿片类药物未耐受初次TKA和THA患者(n=1822)。
  • 阿片类药物未耐受定义为术前90天内未服用任何阿片类药物。
  • 2017年1月至7月未纳入评估,因部分提供者在指南制定期间已早期采纳。

主要发现

  • 指南实施后阿片类药物处方中位数及范围较实施前下降(750 OME,四分位距575-900 OME vs 388 OME,四分位距350-389;中位数差值362 OME;p<0.001)。
  • TKA患者30天续方率在指南实施前后无差异(35%[349/1011] vs 35%[141/399];p=0.77)。
  • THA患者30天续方率在指南实施前后无差异(16%[129/811] vs 17%[61/352];p=0.55)。
  • 控制相关患者层面因素后,机构指南实施是与处方量≤400 OME相关的最强因素(调整比值比36;95%CI 25-52;p<0.001),尽管多种患者层面因素也与处方量相关,但效应量小得多。
  • 指南实施前后两时期患者在年龄、性别、种族、体质指数、教育水平、就业状况、精神疾病、婚姻状况、吸烟史、门诊使用苯二氮䓬类或加巴喷丁类药物、糖尿病、周围神经病变或癌症诊断方面无差异。

关键数值与推荐

  • 新机构指南推荐TKA和THA患者术后最大处方量为400口服吗啡当量(OME),相当于50片5 mg羟考酮或80片50 mg曲马多。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为机构指南减少术后阿片类药物处方可在短时间内改善关节置换术患者的后续照护,属概念验证。
  • 作者指出需要更长期数据以确定纵向指南依从性及试验性计划建立的截断值是否需要针对各手术进一步细化。

局限性

  • 当前报告评估了该计划前5个月的经验,因此需要更长期数据以确定纵向指南依从性以及试验性计划建立的截断值是否需要针对各手术进一步细化。
  • 2017年1月至7月未纳入评估,因部分提供者在指南制定期间已早期采纳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Opioid prescription management is challenging for orthopaedic surgeons, and we lack evidence-based guidelines for responsible opioid prescribing. Our institution recently developed opioid prescription guidelines for patients undergoing several common orthopaedic procedures including TKA and THA in an effort to reduce and standardize prescribing patterns. QUESTIONS/PURPOSES: (1) How do opioid prescriptions at discharge and 30-day refill rates change in opioid-naïve patients undergoing primary TKA and THA before and after implementation of a novel prescribing guideline strategy? (2) What patient, surgical, and in-hospital factors influence opioid prescription quantity and refill rate? METHODS: New institutional guidelines for patients undergoing TKA and THA recommend a maximum postoperative prescription of 400 oral morphine equivalents (OME), comparable to 50 tablets of 5 mg oxycodone or 80 tablets of 50 mg tramadol. All opioid-naïve patients, defined as those who did not take any opioids within 90 days preceding surgery, undergoing primary TKA and THA at a single tertiary care institution were evaluated from program initiation on August 1, 2017, through December 31, 2017, as the postguideline era cohort. This group (n = 751 patients) was compared with all opioid-naïve patients undergoing TKA and THA from 2016 at the same institution (n = 1822 patients). Some providers were early adopters of the guidelines as they were being developed, which is why January to July 2017 was not evaluated. Patients in the preguideline and postguideline eras were not different in terms of age, sex, race, body mass index, education level, employment status, psychiatric illness, marital status, smoking history, outpatient use of benzodiazepines or gabapentinoids, or diagnoses of diabetes mellitus, peripheral neuropathy, or cancer. The primary outcome assessed was adherence to the new guidelines with a secondary outcome of opioid medication refills ordered within 30 days from any provider. Multivariable logistic regression analyses were performed with outcomes of guideline compliance and refills and adjusted for demographic, surgical, and patient care factors. Patients were followed for 30 days after surgery and no patients were lost to followup. RESULTS: Median opioid prescription and range of prescriptions decreased in the postguideline era compared with the preguideline era (750 OME, interquartile range [IQR] 575-900 OME versus 388 OME, IQR 350-389; difference of medians = 362 OME; p < 0.001). There was no difference among patients undergoing TKA before and after guideline implementation in terms of the 30-day refill rate (35% [349 of 1011] versus 35% [141 of 399]; p = 0.77); this relationship was similar among patient undergoing THA (16% [129 of 811] versus 17% [61 of 352]; p = 0.55). After controlling for relevant patient-level factors, we found that implementation of an institutional guideline was the strongest factor associated with a prescription of ≤ 400 OME (adjusted odds ratio, 36; 95% confidence interval, 25-52; p < 0.001); although a number of patient-level factors also were associated with prescription quantity, the effect sizes were much smaller. CONCLUSIONS: This study provides a proof of concept that institutional guidelines to reduce postoperative opioid prescribing can improve aftercare in patients undergoing arthroplasty in a short period of time. The current report evaluates our experience with the first 5 months of this program; therefore, longer term data will be mandatory to determine longitudinal guideline adherence and whether the cutoffs established by this pilot initiative require further refinement for individual procedures. LEVEL OF EVIDENCE: Level II, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Wyles CC, Hevesi M, Trousdale ER, et al. The 2018 Chitranjan S. Ranawat, MD Award: Developing and Implementing a Novel Institutional Guideline Strategy Reduced Postoperative Opioid Prescribing After TKA and THA. Clin Orthop Relat Res. 2019. PMID: 30794233. doi:10.1007/s11999.0000000000000292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。